David Schenkein

Dr. David P.
Schenkein, MD, is an Independent Director at Regeneron Pharmaceuticals, Inc., an Independent Director at Prime Medicine, Inc., a General Partner at GV Management Co. LLC and an Independent Director at Denali Therapeutics, Inc. He is on the Board of Directors at Regeneron Pharmaceuticals, Inc., Prime Medicine, Inc., Denali Therapeutics, Inc., Biotechnology Innovation Organization, Transcend Therapeutics, Inc. (New York), Treeline Biosciences, Inc. and Leyden Laboratories BV.
Dr. Schenkein was previously employed as an Independent Director by bluebird bio, Inc., an Independent Director by Blueprint Medicines Corp., an Independent Director by Foundation Medicine, Inc., an Independent Director by Agios Pharmaceuticals, Inc., a Senior Vice President-Oncology Development by Genentech, Inc., a Senior Vice President-Clinical Research by Takeda Oncology Co., a Venture Partner by ARCH Venture Partners LLC, and an Associate Professor by Tufts Medical Center, Inc. He also served on the board at bluebird bio Inc /Private Group/.
He received his undergraduate degree from Wesleyan University and a doctorate degree from SUNY Upstate Medical University.